UCB is a global biopharmaceutical company headquartered in Brussels, Belgium that focuses on neurology and immunology.
The company has more than 7,5000 employees, a strong market presence in about 40 countries, € 4.5 billion in revenue (2017) and numerous strategic partnerships across the industry.
Their core products are Cimzia®, Vimpat®, Neupro®, Keppra® and Briviact®, and they are preparing the launch of a potential medicine to help patients with osteoporosis.
UCB has been undergoing a far-reaching digital business transformation, integrating novel approaches across its R&D organisation, including Computer-Aided Drug Design (CADD) and AI, while striving to maintain a patient-centric focus.…
Digitalisation has become a buzz word in in the global life sciences sector. In Italy, digital transformation has taken on special significance as one of the principal goals encompassed in…
UCB Italy’s Managing Director, Federico Chinni offeres his insights into UCB’s positioning and its new product launches, the first for the company in ten years. He also weighs in on…
UCB’s general manager for Iberia, Pau Ricós, comments on the Belgian company’s upcoming launches, its focus on immunology and neurology, and the importance of R&D – UCB spent around 28…
Belgian champion UCB’s global manufacturing head, Jacques Marbehant, talks candidly about managing a broad global manufacturing and supply chain through the COVID-19 pandemic, the talent challenges inherent in scaling up…
UCB’s Omar Lugo Aguirre outlines the company’s response to the COVID-19 pandemic in Mexico, countering stigmas around neurodegenerative and mental diseases, and the abundant opportunities that Mexico and the region…
After reaching revenues of EUR 2.323 billion in the first six months of 2019, UCB announced on December 18 that it will build an innovative multi-product biological manufacturing facility on…
Jean-Christophe Tellier became UCB’s CEO on January 1, 2015 only a few years joining the company in 2011. Before taking on the role Tellier held positions as executive VP of…
Jesús Sobrino, area head of UCB Iberia, and global leader for UCB’s Patients Experience Program, discusses the significance of the affiliate, which makes up 15 percent of UCB’s European sales,…
Newly-appointed general manager of UCB France, Catherine Rives, discusses what drew her back to the company after time away, market access issues in France and the future of personalized medicine.…
Albin Egger, country representative of UCB Pharma Austria, discusses the strong performance of the Austrian affiliate within the global group, organizational restructuring, and the receptiveness of Austria to UCB’s innovative…
Nicolas Hug reveals how UCB´s new facility in Bulle, Switzerland, is one of the largest microbial derived pharmaceuticals plants in Europe; how the key challenge for manufacturers today is to…
See our Cookie Privacy Policy Here
